Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria

Richard J. Kelly, Matthew Holt, Jennifer Vidler, Louise M. Arnold, Joanna Large, Briony Forrest, Catherine Barnfield, Alexandra Pike, Morag Griffin, Talha Munir, Petra Muus, Sateesh K. Nagumantry, Abraham Varghese, John R. Davies, Roochi Trikha, Austin G. Kulasekararaj, Lindsay Mitchell, Shreyans Gandhi

Blood (2024) 143 (12): 1157–1166.

https://doi.org/10.1182/blood.2023021762

Published: 2024

Journal Articles

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Blood (2023) 142 (Supplement 1): 636.

https://doi.org/10.1182/blood-2023-174750

Published: 2023

Journal Articles

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 325.

https://doi.org/10.1182/blood-2023-185852

Published: 2023

Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 1660.

https://doi.org/10.1182/blood-2023-180048

Published: 2023

Journal Articles

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

Andy Rawstron, Nichola Webster, Surita Dalal, Ruth M de Tute, Sue Bell, David Allan Cairns, Sean Girvan, Natasha Greatorex, Anna Hockaday, Sharon Jackson, David Phillips, David Stones, David Allsup, Adrian John Clifton Bloor, Anita Sarma, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen

Blood (2023) 142 (Supplement 1): 632.

https://doi.org/10.1182/blood-2023-187943

Published: 2023

Journal Articles

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2023-181108

Published: 2023

Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 3026.

https://doi.org/10.1182/blood-2023-181309

Published: 2023

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 981.

https://doi.org/10.1182/blood-2023-181627

Published: 2023

Journal Articles

Paroxysmal Nocturnal Haemoglobinuria (PNH) Arising from Non-Canonical Mutations

Alexandra Pike, Stephen John Richards, Claire E McKinley, Louise M Arnold, Abraham Mullasseril Varghese, Talha Munir, Petra Muus, Peter Hillmen, Morag Griffin, Richard J Kelly, Darren Newton

Blood (2023) 142 (Supplement 1): 4097.

https://doi.org/10.1182/blood-2023-188755

Published: 2023

Journal Articles

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Blood (2023) 142 (Supplement 1): 634.

https://doi.org/10.1182/blood-2023-177713

Published: 2023

Journal Articles

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Blood (2023) 142 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2023-180527

Published: 2023

Journal Articles

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Blood (2023) 142 (Supplement 1): 631.

https://doi.org/10.1182/blood-2023-178298

Published: 2023

Journal Articles

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

Blood (2023) 142 (Supplement 1): 4636.

https://doi.org/10.1182/blood-2023-188597

Published: 2023

Journal Articles

52-Week Open-Label Extension Data from a Phase 2 Study Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switched from Eculizumab

Richard J. Kelly, Nicola Houghton, Talha Munir, Petra Muus, Nora Youngs, Lisa Aurand, Kosalai Mohan, Brian Senk, Rodrigo Pavani, Lorah Perlee, Amal Souttou, Morag Griffin

Blood (2023) 142 (Supplement 1): 2716.

https://doi.org/10.1182/blood-2023-188671

Published: 2023

Journal Articles

Sars-Cov-2 Antibody and T-Cell Responses in Patients with Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia after Four COVID-19 Vaccinations

Blood (2023) 142 (Supplement 1): 2712.

https://doi.org/10.1182/blood-2023-190393

Published: 2023

Journal Articles

Zanubrutinib vs FCR in Fit Treatment-Naive Patients with Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

Talha Munir, Leyla Mohseninejad, Sheng Xu, Milica Jevdjevic, Walter Bouwmeester, Keri Yang

Blood (2023) 142 (Supplement 1): 6522.

https://doi.org/10.1182/blood-2023-173172

Published: 2023

Journal Articles

A Phase 1 Study Evaluating PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Select Relapsed/Refractory B-Cell Malignancies

Bruce D. Cheson, Geoffrey P. Shouse, Sarit Assouline, Katharine L. Lewis, Eliza A Hawkes, Talha Munir, Andrew S. Davies, Petra Langerbeins, Constantine S. Tam, Gareth P. Gregory, Michael Y. Choi, William Sun, Siminder K. Atwal, Wan-Jen Hong, Clémentine Sarkozy

Blood (2023) 142 (Supplement 1): 6324.

https://doi.org/10.1182/blood-2023-182434

Published: 2023

Journal Articles

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O’Brien, Jennifer R. Brown, Talha Munir, Anthony Mato, Stephan Stilgenbauer, Naghmana Bajwa, Paulo Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach

Blood (2023) 142 (8): 687–699.

https://doi.org/10.1182/blood.2022018818

Published: 2023

Includes: Supplemental data

Journal Articles

Experience of compassionate-use pegcetacoplan for paroxysmal nocturnal hemoglobinuria

Morag Griffin, Petra Muus, Talha Munir, Sateesh Nagumantry, Alexandra Pike, Louise Arnold, Briony Forrest, Catherine Barnfield, Nicola Houghton, Nora Youngs, Richard Kelly

Blood (2023) 141 (1): 116–120.

https://doi.org/10.1182/blood.2022017266

Published: 2023

Journal Articles

Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Andrea Visentin, Lydia Scarfò, Thomas Chatzikonstantinou, Anargyros Kapetanakis, Christos Demosthenous, Georgios Karakatsoulis, Martin Andres, Darko Antic, David Allsup, Mónica Baile, Dominique Bron, Antonella Capasso, Mark Catherwood, Rosa Collado, Raul Cordoba, Carolina Cuéllar-García, Julio Delgado, Maria Dimou, Michael Doubek, Lorenzo De Paoli, Maria Rosaria De Paolis, Giovanni Del Poeta, Maria Efstathopoulou, El-Ashwah Shimaa, Alicia Enrico, Lucia Farina, Angela Ferrari, Myriam Foglietta, Moritz Furstenau, Jose A. Garcia-Marco, Massimo Gentile, Eva Gimeno, Gomes da Silva Maria, Odit Gutwein, Yervand Hakobyan, Yair Herishanu, jose Angel Hernandez, Tobias Herold, Sunil Iyengar, Gilad Itchaki, Ozren Jaksic, Ann Janssens, Olga Kalashnikova, Elzbieta Kalicinska, Arnon P. Kater, Sabina Kersting, Jorge Labrador, Deepesh Lad, Luca Laurenti, Mark-David Levin, Enrico Lista, Lara Malerba, Roberto Marasca, Monia Marchetti, Juan Marquet Palomanes, Mattias Mattsson, Francesca Romana Mauro, Carlota Mayor-Bastida, Marta Morawska, Marina Motta, Talha Munir, Roberta Murru, Ivana Milosevic, Fatima Miras Calvo, Carsten Utoft Niemann, Jacopo Olivieri, Lorella Orsucci, Maria Papaioannou, Miguel Arturo Pavlovsky, Inga S. Piskunova, Barbara Pocali, Viola Maria Popov, Francesca Maria Quaglia, Giulia Quaresmini, Doreen te Raa, Gianluigi Reda, Gian Matteo Rigolin, Rosa Ruchlemer, Amit Shrestha, Martin Šimkovič, Martin Špaček, Paolo Sportoletti, Oana Stanca Ciocan, Tamar Tadmor, Elisabeth Vandenberghe, Marzia Varettoni, Candida Vitale, Ellen Van Der Spek, Michel Van Gelder, Ewa Wasik-Szczepanek, Lucrecia Yáñez, Mohamed A Yassin, Marta Coscia, Barbara Eichhorst, Alessandro Rambaldi, Niki Stavroyianni, Livio Trentin, Kostas Stamatopoulos, Paolo Ghia

Blood (2022) 140 (Supplement 1): 2333–2337.

https://doi.org/10.1182/blood-2022-163259

Published: 2022

NARROW

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Paroxysmal Nocturnal Haemoglobinuria (PNH) Arising from Non-Canonical Mutations

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

52-Week Open-Label Extension Data from a Phase 2 Study Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switched from Eculizumab

Sars-Cov-2 Antibody and T-Cell Responses in Patients with Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia after Four COVID-19 Vaccinations

Zanubrutinib vs FCR in Fit Treatment-Naive Patients with Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

A Phase 1 Study Evaluating PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Select Relapsed/Refractory B-Cell Malignancies

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

Experience of compassionate-use pegcetacoplan for paroxysmal nocturnal hemoglobinuria

Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only